All In Biotech

Drug Trial Radar · NCT04022291

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

A Randomised, Double-blind, Two-period Crossover, Euglycaemic Glucose Clamp Study in Healthy Volunteers to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity of Biocon Insulin 70/30 and Humulin® 70/30

Last checked: Nov 20, 2026Latest source record: Jan 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jun 15, 2019

Primary completion

Jan 20, 2020

Study completion Jan 27, 2020

Sponsor

Lead sponsor
Biocon LimitedIndustry
Sponsor type
Industry
Collaborators
Profil Institut für Stoffwechselforschung GmbH
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Two-centre, randomised, double-blind, single dose, two-treatment, two-period, two sequence, crossover, 24-hour euglycaemic glucose clamp trial in healthy subjects.

Conditions

  • Healthy Volunteer

Interventions

  • Humulin ®70/30Biological

    Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin. Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.

  • Biocon Insulin 70/30Biological

    Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin. Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic endpoints: area under the insulin concentration curve (AUCins) 0-24hTime frame: 0-24hour
  2. Pharmacokinetic endpoints: insulin concentration (Cins).maxTime frame: 0-24hour
  3. Pharmacodynamic Endpoint: Area under curve (AUC)Glucose infusion rate (GIR).0-24hTime frame: 0-24hour
  4. Pharmacodynamic Endpoint: maximum glucose infusion rate (GIRmax)Time frame: 0-24hour

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116

    Mainz, Germany

  • Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss

    Neuss, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.